Adherence and resource use among psoriasis patients treated with biologics

Aleshaki, Joseph S.; Cardwell, Leah A.; Muse, Mikel E.; Feldman, Steven R.

doi:10.1080/14737167.2018.1512408

Cited by 18 publications

(18 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In total, nine treatment‐related factors were identified to have clear associations (change in or lack of efficacy, biologic type, concurrent therapies, rescheduling of appointments, affordability, side effects, and initial dosage, frequent follow‐up, history of adherence to any psoriasis medications). The presence of concurrent therapies and frequent follow‐up were positively correlated to higher adherence 4,12 . A change in or lack of efficacy, side effects, rescheduling of appointments, decreased affordability, and increased initial dosage were all associated with decreased adherence rates 4,8 .…”

Section: Resultsmentioning

confidence: 97%

“…Regarding biologic therapy specifically, three SRs were identified 4,8,12,13 . In total, nine treatment‐related factors were identified to have clear associations (change in or lack of efficacy, biologic type, concurrent therapies, rescheduling of appointments, affordability, side effects, and initial dosage, frequent follow‐up, history of adherence to any psoriasis medications).…”

Section: Resultsmentioning

confidence: 99%

“…Two SRs regarding adherence to biologic psoriasis medications were identified 4,12 . In total, four psychosocial factors were explored (anxiety, forgetfulness, experience, and reframing).…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

A narrative review of systematic reviews on adherence to psoriasis treatments

Feldman

Rakita

Porter

et al. 2021

Dermatological Reviews

Self Cite

View full text Add to dashboard Cite

Introduction: Psoriasis is a prevalent disorder of the skin which presents with scaly, red plaques and leads to significant morbidity and mortality. Thus, successful treatment is of great importance to the patient and provider. Objective: Nonetheless, a significant cause of treatment failure may not be incorrect diagnosis or treatment, but rather nonadherence. We aimed to elucidate what factors influence adherence to psoriasis treatments. Methods: We conducted a review on the literature on adherence by adapting search terms derived from an existing systematic review (SR) on psoriasis adherence. Only data relevant to patients with psoriasis were extracted, including the type of medications they were using, when available. All of the factors associated with adherence were grouped by medication type and whether they had positive, negative, or no association with adherence, or mixed evidence. Results: We found a unifying theme across SR was the wide heterogeneity in methodology of primary studies. There are pearls to be gleaned from this review, such as the power of a well‐written prescription, shared decision‐making, using effective treatments, having frequent follow‐up, and reframing adverse effects to improve adherence. Conclusion: There is widespread prevalence of both mixed and contradicting conclusions across the SR, which may stem from the fact that studies on adherence vary extensively in their definition of adherence, their method for evaluating it, and their patient populations.

show abstract

Section: Resultsmentioning

confidence: 97%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

A narrative review of systematic reviews on adherence to psoriasis treatments

Feldman

Rakita

Porter

et al. 2021

Dermatological Reviews

Self Cite

View full text Add to dashboard Cite

show abstract

“…A previous analysis of the current/ 18 preceding 26 study data demonstrated an absence of neutralizing anti‐brodalumab antibodies. Therefore, the lack of efficacy in non‐responders could be related to poor adherence, given that adherence to biologics is reported to be suboptimal 27 . Moreover, self‐administration of brodalumab was permitted from Day 1.…”

Section: Discussionmentioning

confidence: 99%

Relationship between serum trough levels and efficacy of brodalumab from a post hoc exploratory analysis of a Japanese study in patients with plaque psoriasis

Yamaguchi

Kanai

Kitabayashi

et al. 2020

The Journal of Dermatology

View full text Add to dashboard Cite

Previous clinical studies have shown that efficacy and serum brodalumab levels are dose dependent in patients with psoriasis receiving the same dose of brodalumab during the study. This study aimed to investigate the association between dosage, serum levels, and efficacy of brodalumab in Japanese patients with plaque psoriasis with dosage variations during the study. This was a post hoc exploratory analysis of a 108‐week, multicenter, open‐label extension study, which changed into a post‐marketing surveillance study following brodalumab approval in Japan. Eligible patients with plaque psoriasis (n = 129) received brodalumab 140 mg every 4 weeks on Day 1; dosage change at physician’s discretion from 140 mg every 8 weeks to 210 mg every 2 weeks was permitted; patients switched to 210 mg every 2 weeks during the post‐marketing surveillance study. Exploratory endpoints included serum brodalumab levels at Weeks 28 and 108, its association with Psoriasis Area and Severity Index score, and Psoriasis Area and Severity Index score in patients receiving brodalumab 210 mg every 2 weeks at end of study. Median brodalumab trough levels were significantly higher (P < 0.05) at higher vs. lower dosages at Weeks 28 (n = 126) and 108 (n = 111) except for 140 mg every 2 weeks vs. 210 mg every 2 weeks at Week 108 and higher in patients with lower Psoriasis Area and Severity Index scores—significantly different only for Psoriasis Area and Severity Index score 0 vs. >2 at Week 28 (P = 0.0153). Of 100 patients receiving 210 mg every 2 weeks at end of study, 89% had a Psoriasis Area and Severity Index score ≤2. In patients with plaque psoriasis, brodalumab efficacy may depend upon sustained serum trough levels and can be restored by using the approved dose.

show abstract

“…It may be influenced by different factors. Adherence can be higher when income increases, in richer geographic areas, or in psoriasis patients visiting rheumatologists (1,2) whereas it could decrease when additional comorbidities or stressful situations take place and when self-administered medication is prescribed (3,4). From March 2020 to date, we have faced the large-scale spread of SARS-CoV-2 virus, which has posed new challenges in the organization and operation of hospitals and pharmacy departments.…”

Section: Introductionmentioning

confidence: 99%

Intense Impact of Health Alert Due to COVID-19 on Adherence of Moderate to Severe Psoriasis Patients to Hospital Therapy

et al. 2021

View full text Add to dashboard Cite

Background: Psoriasis is a chronic skin disease in which lifelong treatment is required. Recently, we faced COVID-19 pandemic where adherence to a prescribed drug could have been affected. Objectives: We conduct a study to assess this statement. Methods: The study was performed in Dermatology Department with Pharmacy database in the Hospital Universitario de La Princesa. A retrospective observational database study was performed, including all psoriatic patients with a biological therapy prescription between March 13 and May 31, 2020, with a paired control group between March 13 and May 31, 2019. Medication possession ratio (MPR) was used to determine the adherence. Results: A total of 244 patients were included in the cohort and 228 in the control group. We observed a decrease in the percentage of adherent patients of 40.0% in COVID-19 period. Overall, MPR was lower in the 2020 period than in 2019. MPRs by treatment and drug family, with the exception of etanercept, certolizumab pegol, and guselkumab, were significantly lower between the 2019 and the 2020 period. Conclusions: Adherence to a prescribed drug can be affected by different factors such as age, sex, income quintile, or stress. We have demonstrated a deep impact on adherence because of the situation created by COVID-19 pandemic. These data are in contrast with previously reported results where adherence was slightly affected, probably due to the different epidemiological situation in different countries. Further efforts are needed to be done to mitigate COVID-19 pandemic influence on the therapeutic adherence.

show abstract

Adherence and resource use among psoriasis patients treated with biologics

Cited by 18 publications

References 31 publications

A narrative review of systematic reviews on adherence to psoriasis treatments

A narrative review of systematic reviews on adherence to psoriasis treatments

Relationship between serum trough levels and efficacy of brodalumab from a post hoc exploratory analysis of a Japanese study in patients with plaque psoriasis

Intense Impact of Health Alert Due to COVID-19 on Adherence of Moderate to Severe Psoriasis Patients to Hospital Therapy

Contact Info

Product

Resources

About